GEXVal's Lead Program GXV-001 Receives FDA Rare Pediatric Disease Designation

株式會社GEXVal
November 18, 2026

GEXVal's Lead Program GXV-001 Receives Rare Pediatric Disease Designation from the U.S. FDA
Working to bring new options to children with Fragile X syndrome and their families as soon as possible

GEXVal Inc. (President & CEO: Juran Kato, PhD; Fujisawa, Kanagawa, Japan; hereinafter "GEXVal") announces that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to its lead program GXV-001 for Fragile X syndrome (FXS).

FXS is a rare genetic condition arising from changes in the FMR1 gene, and its characteristics often become apparent in early childhood. This designation follows the Orphan Drug Designation (ODD) granted by the FDA in November 2025, and marks a new step in research built with the support of FRAXA Research Foundation (FRAXA).

With gratitude to people with FXS and their families, and to the community that has supported this research for many years, GEXVal remains committed to advancing development so that new options can reach them as soon as possible.

■ About Rare Pediatric Disease Designation (RPDD)
The FDA grants RPDD to investigational drugs for serious or life-threatening conditions that primarily affect individuals from birth to 18 years of age and affect fewer than 200,000 people in the United States. If a designated drug is later approved and meets certain criteria, the sponsor may be eligible for a Priority Review Voucher (PRV), which can be used to obtain priority review of a different drug application. The program, which lapsed in December 2024, was reauthorized through September 30, 2029, under U.S. appropriations legislation enacted in February 2026. This designation does not constitute approval of safety or efficacy.

For more information: U.S. FDA, "Rare Pediatric Disease Designation and Priority Review Voucher Programs" (content current as of April 29, 2026)
URL: https://www.fda.gov/rare-pediatric-disease-priority-review-voucher-program

■ About GXV-001
Based on nonclinical study results and other data, GXV-001 received ODD from the FDA in November 2025 and has now received RPDD. In a Phase 1 study (single and multiple ascending doses) in healthy young adults and elderly subjects conducted through our Australian subsidiary, the safety, tolerability, and pharmacokinetic profiles were confirmed as planned, and target engagement assessments were also completed. Building on scientific advice received from the European Medicines Agency (EMA) in May 2026, GEXVal is preparing to initiate a Phase 2a clinical trial in Europe. GXV-001 is being developed globally through ongoing dialogue with regulators across regions, including the Phase 1 study in Australia, scientific advice from the EMA, and designations from the FDA.

*For details, please see our news releases dated November 19, 2025, and May 21, 2026.
 November 19, 2025 news release:
GEXVal Receives FDA Orphan Drug Designation for GXV-001 in Fragile X Syndrome

May 21, 2026 news release:
GEXVal Receives EMA’s CHMP Scientific Advice for Lead Pipeline GXV-001

■ Our Journey with FRAXA (FRAXA Research Foundation)
FRAXA is a nonprofit organization headquartered in Massachusetts, USA, founded in 1994 by families of children with FXS. It supports the development of treatments for FXS through research grants to institutions around the world, including in North America and Europe, and through partnerships with pharmaceutical and biotech companies. FRAXA also runs the FRAXA Drug Validation Initiative (FRAXA-DVI), which evaluates drug candidates using FXS mouse models. https://www.fraxa.org

Through this program, GXV-001 completed studies evaluating multiple behavioral measures*. This RPDD builds on our collaboration with FRAXA. GEXVal continues to receive support from FRAXA for the next stage of development, including site selection for the planned Phase 2a trial in Europe and connections with FXS research communities in multiple countries.
*For details, please see our news release dated February 28, 2026.

■ About Fragile X Syndrome (FXS)
FXS is a rare genetic condition in which changes in the FMR1 gene lead to loss of function of the FMRP protein. In Japan, FXS is designated as Designated Intractable Disease No. 206. Many people with FXS show features of autism spectrum disorder, and characteristics, which vary from person to person, may include attention difficulties and hyperactivity, anxiety, sensory sensitivities, intellectual disability, epilepsy, and sleep difficulties. According to FRAXA, FXS is the most common known genetic cause of autism and intellectual disability, occurring in approximately 1 in 2,400 to 6,000 births. While diagnosis is more common in Europe and North America, many people with FXS in Japan are thought to remain undiagnosed. There are currently no approved treatments for FXS.

For more information:
- National Organization for Rare Disorders (NORD): https://rarediseases.org/rare-diseases/fragile-x-syndrome/
- Orphanet: https://www.orpha.net/en/disease/detail/908

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, in pursuit of our mission Treatment Reaching the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

This announcement is intended to report on GEXVal's research results and development status, and is not intended to claim the efficacy of, or to advertise or promote, any pharmaceutical product. GXV-001 is an investigational drug candidate that has not been approved, and its efficacy and safety in humans have not been established.

有關本事宜請諮詢:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com